Our assessments were further extended to the state of tumour metabolism in ccRCC samples labelled for the proliferative Ki-67, indoleamine 2,3-dioxygenase-1 (IDO-1), GLUT-1, and CD73 markers, but no difference was noted in inhibitory tumour metabolism among the three groups (Fig. 2e). The gene discussed is IDO1; the disease is nonpapillary renal cell carcinoma.